1. Scrip
  2. >>Therapy Areas

Fate of Avastin in early-stage cancer uncertain after second Phase III failure in colon cancer

 
• By Malini Guha

Roche is facing further disappointment with its top selling drug, Avastin (bevacizumab) – which is so far approved for advanced/metastatic cancer in a number of tumour types – after the anti-angiogenic agent failed in its second Phase III trial in early-stage colon cancer to reduce the risk of disease recurrence. Meanwhile, the FDA has delayed its much-anticipated decision on Avastin's use in metastatic breast cancer after the company submitted new information.

Roche is facing further disappointment with its top selling drug, Avastin (bevacizumab) – which is so far approved for advanced/metastatic cancer in a number of tumour types – after the anti-angiogenic agent failed in its second Phase III trial in early-stage colon cancer to reduce the risk of disease recurrence. Meanwhile, the FDA has delayed its much-anticipated decision on Avastin's use in metastatic breast cancer after the company submitted new information.

The failure of Avastin to improve disease-free survival (DFS) in early-stage colon cancer in the Roche-sponsored AVANT trial looks likely to seal its fate in this indication (although Roche and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapeutic Category

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.